Comparison of hybrid capture and reverse transcriptase polymerase chain reaction methods in terms of diagnosing human cytomegalovirus infection in patients following hematopoietic stem cell transplantation

Saudi Medical Journal

Volumn 27, Issue 7, 2006, Pages 967-974

  Orsal, Arif S ^a   Ozsan, Murat ^a   Dolapci, Istar ^a   Tekeli, Alper ^a   Beksac, Meral ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FEMALE; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MALE; NUCLEIC ACID HYBRIDIZATION; PREDICTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TURKEY (REPUBLIC); VIREMIA;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; POSTOPERATIVE COMPLICATIONS; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 33750289733     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Apperley JF, Goldman JM. Cytomegalovirus. Biology, clinical features and methods for diagnosis of bone marrow transplantation. Bone Marrow Transplant 1988; 3: 253-264.
2. Pillay D, Webster A, Prentice HG, Griffiths PD. Risk factors for viral reactivation following bone marrow transplantation. Ann Hematol 1992; 64(Suppl): A148-151.
3. Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 1996; 100: 59-63.
4. Boeckh MJ, Ljungman P. Cytomegalovirus infection after hemopoietic stem cell transplantation. In: Bowden RA, Ljungman P, Paya VP, editors. Transplant Infections. Philadelphia; Lippincott, Williams & Wilkins: 2002.
5. Einsele H, Hebart C, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, et al Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
6. Singh A. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742-751.
7. Kanda S, Chiba T, Suzuki M, Kami M, Yazaki Y, Hirai H. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.
8. Gerna F, Baldanti JM, Middeldorp M, Furione M, Zavattoni M, Lilleri D, et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1999; 37: 902-911.
9. Mocarski ES, Courcelle CT. Cytomegalovirus and their replication. In: Knipe D, Howley P, editors. Fields Virology. Philadelphia; Lippincott, Williams and Wilkins. 2001. p. 2629-2673.
10. Boriskin YS, Fuller K, Powles RL, Vipond IB, Rice PS, Booth JC, et al. Early detection of cytomegalovirus infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation. J Clin Virol 2002; 24: 13-23.
11. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172-1179.
12. Nelson PN, Rawal BK, Boriskin YS, Mathers KE, Powles RL, Steel HM et al. A polymerase chain reaction to detect a spliced late transcript of human cytomegalovirus in the blood of bone marrow transplant recipients. J Virol Methods 1996; 56: 139-148.
13. Sasieni PD. Statistical analysis of the performance of diagnostic tests. Cytopathology 1999; 10: 73-78.
14. Mengoli C, Cusinato R, Biasolo MA, Cesaro S, Parolin C, Palu G. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J Med Virol 2004; 74: 78-84.
15. Boriskin YS, Rice PS, Stabler RA, Hinds J, Al-Ghusein H, Vass K, et al. DNA microarrays for virus detection in cases of central nervous system infection. J Clin Microbiol 2004; 42: 5811-5818.
16. Mazzulli T, Drew LW, Yen-Lieberman B, Jekic-McMullen D, Kohn DJ, Isada C, et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999; 37: 958-963.
17. Wattal C, Joshi S, Gupta A, Sharma A, Oberoi JK, Prasad KJ, et al. The pp67 mRNA assay in treatment and monitoring of cytomegalovirus disease in renal transplant patients in India. Transpl Infect Dis 2004; 6: 90-92.
18. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther 2003; 983: 269-297.
19. Ljungman PJ, Aschan I, Lewensohn-Fuchs S, Carlens K, Larsson B, Lonnqvist J, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330.
20. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
21. Voisset C, Mandrand B, Paranhos-Baccala G. RNA amplification technique, NASBA, also amplifies homologous plasmid DNA in non-denaturing conditions. Bio Techniques 2000; 29: 236-240.
22. Meyer T, Reischl U, Wolf H, Schuller C, Arndt R. Identification of active cytomegalovirus infection by analysis of immediate-early, early and late transcripts in peripheral blood cells of immunodeficient patients. Mol Cell Probes 1994; 8: 261-271.
23. Mullberg J, Hsu ML, Rauch CT, Gerhart MJ, Kaykas A, Cosman D. The R27080 glycoprotein is abundantly secreted from human cytomegalovirus-infected fibroblasts. J Gen Virol 1999; 80: 437-440.
24. Rawlinson WD, Barell BG. Spliced transcripts of human cytomegalovirus. J Virol 1993; 67: 5502-5513.
25. Greijer AE, Van De Crommert, Stevens JMG, Middeldorp JM. Molecular fine-specificity analysis of antibody response to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays. J Clin Microbiol 1999; 37: 179-188.
26. Ozsan M, Erbay B, Ozkul A, Erturk S, Karaarslan A, Ates K. Serological and clinical follow up of cytomegalovirus infection in renal transplant patients and prevalence of symptom infection after transplantation. Bulletin of Microbiology 1999; 33: 127-134.
27. Topcuoglu P, Arat M, Soydan E, Dalva K, Ciftcioglu A, Akan H, et al. Occurrence of cytomegalovirus infection and/or viremia shortens overall survival. Bone Marrow Transplantation 2004; 33 (Suppl 1): 203-204.
28. Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
29. D'Agaro P, Andolina M, Burgnich P, Samar E, Campello C. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years experience. Haematologica 2000; 85: 54-57.
30. Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001; 28: 765-768.
31. Machado CM, Menezes RX, Macedo MCA, Mendes AVA, Villas Boas LS, Castelli JV, et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-1059.
32. Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618.
33. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient sero-status, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484-1490.
34. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/ recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
35. Griffiths PD, Clark DA, Emery VC. Betaherpesviruses in transplant recipients. J Antimicrob Chemother 2000; 45 Suppl T3: 29-34.
36. Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002; 74: 49-54.
37. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrosand outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 801-807.
38. Mandanas RA, Saez RA, Selby GB, Confer DL. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy. Am J Hematol 1996; 51: 104-111.
39. Maeda Y, Teshima T, Yamada M, Shinagawa K, Nakao S, Ohno Y, et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol 1999; 105: 295-302.
40. Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, et al. Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation. Bone Marrow Transplant 2003; 32: 703-707.
41. Trenschel R, Ross S, Husing JI. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665-672.
42. Gerna G, Baldantia F, Revelloa MG. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 2004; 65: 381-386.
43. Smith MS, Bentz GL, Alexander JS, Yurochko AD. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol 2004; 78: 4444-4453.
44. Gerna G, Baldanti F, Lilleri D, Parea M, Alessandrino E, Pagani A, et al. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol 2000; 38: 1845-1853.